List of Excipients in Branded Drug MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Generic Drugs Containing MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Vitruvias Therapeutics Inc	memantine hydrochloride and donepezil hydrochloride	69680-183	BRILLANT BLUE
Vitruvias Therapeutics Inc	memantine hydrochloride and donepezil hydrochloride	69680-183	CELLULOSE, MICROCRYSTALLINE
Vitruvias Therapeutics Inc	memantine hydrochloride and donepezil hydrochloride	69680-183	ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B
Vitruvias Therapeutics Inc	memantine hydrochloride and donepezil hydrochloride	69680-183	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE?

# Of NDCs	Excipient
1	BRILLANT BLUE
1	CELLULOSE, MICROCRYSTALLINE
1	ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B
1	FERRIC OXIDE YELLOW

Memantine Hydrochloride and Donepezil Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

The commercial opportunity for memantine hydrochloride and donepezil hydrochloride is concentrated in fixed-dose combination products, multiparticulate delivery, sprinkle formulations, and differentiated generic or specialty-generic platforms. The reference product, Namzaric, combines extended-release memantine with immediate-release donepezil in four capsule strengths for moderate-to-severe Alzheimer’s disease. The main technical barrier is controlling two release profiles in one dosage form while preserving dose uniformity, stability, capsule-opening performance, and manufacturing scalability.

What product combines memantine hydrochloride and donepezil hydrochloride?

Namzaric is the principal U.S. fixed-dose combination product containing memantine hydrochloride extended release and donepezil hydrochloride immediate release. The product is approved for the treatment of moderate-to-severe dementia of the Alzheimer’s type in patients stabilized on both components.[1]

Product attribute	Namzaric profile
Active ingredients	Memantine hydrochloride and donepezil hydrochloride
Dosage form	Oral hard gelatin capsule
Memantine component	Extended release
Donepezil component	Immediate release
U.S. strengths	7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg, 28 mg/10 mg
Regulatory pathway	New drug application 206439
FDA approval	December 2014
Primary indication	Moderate-to-severe Alzheimer’s disease
Administration	Once daily
Patient-use option	Capsule may be opened and sprinkled on applesauce; contents must not be divided, chewed, or crushed

The product is intended for patients already receiving memantine and donepezil. Its commercial value comes from reducing pill burden and combining the two maintenance therapies in a single once-daily product.

What excipients are used in memantine-donepezil capsules?

The reference formulation uses a multiparticulate design. Memantine is delivered through extended-release pellets, while donepezil is incorporated as an immediate-release component. The capsule shell and pellet coatings complete the dosage form.

The U.S. prescribing information identifies excipient classes that include sugar spheres, povidone, hypromellose, ethylcellulose, talc, polyethylene glycol, triethyl citrate, gelatin, titanium dioxide, and permitted colorants.[1] Exact excipient selection and coating levels are part of the product’s formulation and manufacturing know-how.

Functional role of the excipients

Excipient or excipient class	Primary formulation function	Commercial relevance
Sugar spheres	Inert starter cores for drug-layered pellets	Supports multiparticulate processing and uniform coating
Povidone	Binder and drug-layering aid	Improves adhesion and reduces powder loss
Hypromellose	Film former or matrix-forming polymer	Can support coating integrity and release control
Ethylcellulose	Water-insoluble release-rate membrane	Controls memantine diffusion and reduces dose dumping risk
Talc	Anti-tacking and coating-process aid	Improves pellet coating efficiency
Polyethylene glycol	Plasticizer or coating modifier	Reduces film brittleness
Triethyl citrate	Plasticizer	Improves flexibility of polymer membranes
Gelatin	Capsule shell material	Enables oral delivery and capsule-opening administration
Titanium dioxide and colorants	Capsule identification and appearance	Supports product differentiation and strength recognition

A successful generic or reformulated product does not need to duplicate every excipient qualitatively. It must demonstrate pharmaceutical equivalence, bioequivalence, acceptable stability, and appropriate product performance. Formulation changes can create regulatory risk if they alter memantine release, donepezil exposure, pellet integrity, or sprinkle behavior.

How should the excipient strategy control two release profiles?

The formulation should treat memantine and donepezil as separate delivery systems within one capsule rather than as a conventional homogeneous blend.

Memantine extended-release subsystem

Memantine hydrochloride has high aqueous solubility and can release rapidly without rate control. The formulation therefore needs a robust diffusion barrier or matrix system. Multiparticulate pellets offer several advantages:

• They distribute the dose across many units.
• They reduce the risk that one damaged unit will release the full dose.
• They support capsule opening and sprinkling.
• They provide flexibility in adjusting release without changing the capsule size.
• They can improve dose uniformity across the four strengths.

Ethylcellulose-based membranes, often modified with hydrophilic polymers and plasticizers, are suitable for controlling aqueous ingress and drug diffusion. Coating weight gain, polymer viscosity, pore formation, pellet size, and curing conditions are critical process variables.

Donepezil immediate-release subsystem

Donepezil hydrochloride should dissolve promptly after administration. Its formulation should avoid excessive binding or coating that would delay dissolution. The immediate-release fraction can be incorporated into a drug-layered pellet, powder blend, or separate granulated population, provided that the final capsule meets dissolution and content-uniformity requirements.

The formulation must prevent cross-interference between the donepezil immediate-release fraction and the memantine extended-release pellets. Fine-particle migration, electrostatic segregation, and coating-fragment generation are relevant manufacturing risks.

Capsule and sprinkle performance

The FDA label permits opening the capsule and sprinkling the contents on applesauce.[1] That administration route creates a commercial and regulatory performance requirement. Development testing should evaluate:

1. Recovery of the full labeled dose from the capsule.
2. Content uniformity after transfer to food.
3. Stability during the permitted administration window.
4. Absence of pellet crushing during handling.
5. Maintenance of memantine dissolution after sprinkling.
6. Immediate release of donepezil after administration.
7. Palatability and mouthfeel.

A product that matches dissolution in an intact capsule but fails after sprinkling may not provide a credible substitute for the reference product.

What formulations are protected by the Namzaric patent estate?

The relevant intellectual-property position has historically focused on fixed-dose combinations containing memantine and donepezil, including dosage forms that provide extended-release memantine with immediate-release donepezil. Public litigation has identified U.S. Patent Nos. 8,846,100 and 9,295,657 among patents asserted against potential generic entrants.[2,3]

IP category	Technical subject matter	Competitive impact
Fixed-dose combination	Memantine and donepezil in one oral product	Supports product-level differentiation
Release architecture	Extended-release memantine with immediate-release donepezil	Creates formulation and bioequivalence complexity
Dose combinations	Multiple memantine strengths paired with donepezil	Supports line-extension protection
Multiparticulate delivery	Pellets or other controlled-release units within a capsule	Creates process-development barriers
Administration method	Once-daily treatment for patients receiving both drugs	May support method-of-use or regimen claims
Manufacturing process	Drug layering, coating, curing, and capsule filling	Can create trade-secret and process-control barriers

Patent scope depends on claim language, prosecution history, terminal disclaimers, patent-term adjustment, Orange Book listing, and litigation outcomes. Patent numbers alone do not establish a current blocking position. The FDA Orange Book remains the operative source for listed patents and exclusivity status.[4]

When does memantine-donepezil lose exclusivity?

Namzaric did not receive five-year new chemical entity exclusivity because both active ingredients had already been approved independently. The product could qualify for three-year exclusivity based on new clinical investigations supporting the combination or modified dosage form. FDA approval occurred in December 2014, making the principal three-year exclusivity period relevant through 2017.[1,4]

Patent expiry is separate from regulatory exclusivity. Listed patents may extend beyond the three-year period and can delay or complicate generic approval through Paragraph IV litigation. A commercial launch analysis should separate:

• FDA marketing exclusivity.
• Listed patent expiration.
• Patent-term adjustment.
• Pediatric exclusivity, if granted.
• Six-month stays triggered by patent litigation.
• Settlement-based launch dates.
• State and commercial contracting restrictions.

Because Namzaric is a small-molecule product, biosimilar exclusivity does not apply. Competitive entrants would generally pursue ANDAs, not abbreviated biologics license applications.

Which companies are challenging or could challenge Namzaric?

Potential challengers include established generic companies with capabilities in modified-release oral dosage forms, multiparticulate manufacturing, and complex ANDA development. Public disputes involving Namzaric patents have included challenges by generic manufacturers such as Zydus and other ANDA applicants.[2,3]

The most credible challengers are companies that already manufacture:

• Extended-release pellets.
• Capsule-in-capsule or multiparticulate products.
• Sprinkle formulations.
• Multiple strengths with proportional or nonproportional dose scaling.
• Highly soluble drugs requiring diffusion-controlled release.

A Paragraph IV challenge would need to address both patent invalidity or noninfringement and the technical requirements for a therapeutically equivalent product. A generic applicant can design around a formulation claim, but it must still demonstrate bioequivalence to a product containing two components with different release characteristics.

What generic entry risks exist for memantine-donepezil?

Generic entry risk is moderate to high over the long term but is technically more complex than a standard immediate-release tablet.

Key ANDA development risks

Risk	Why it matters
Dual pharmacokinetic profile	Memantine and donepezil require different release behavior
Dose proportionality	Four strengths must maintain reliable performance
Food effect	Food can alter release from multiparticulate systems
Sprinkle equivalence	Open-capsule administration must remain acceptable
Dissolution matching	Memantine release must track the reference profile
Manufacturing scale-up	Coating uniformity can change at commercial batch size
Capsule segregation	Pellet populations may separate during filling
Patent certification	Paragraph IV litigation may delay approval or launch
Stability	Polymer membranes and gelatin shells can change with humidity
Pharmacovigilance	Both active ingredients have established but distinct adverse-effect profiles

An entrant with an immediate-release memantine component would face a significant therapeutic-equivalence problem because Namzaric uses extended-release memantine. An entrant with a single matrix tablet would also need to demonstrate that its release behavior and exposure are equivalent to the reference capsule.

How strong is the patent estate for memantine-donepezil products?

The patent estate is stronger at the formulation and combination level than at the active-ingredient level. Memantine and donepezil are off-patent active ingredients, so composition-of-matter protection does not provide a barrier. The remaining value is concentrated in:

• The combined dosage form.
• Release-profile architecture.
• Dose strengths.
• Sprinkle administration.
• Manufacturing controls.
• Method-of-use claims.
• Regulatory and commercial execution.

The estate’s practical strength depends on whether the asserted claims cover the specific architecture required for bioequivalence. A narrow formulation claim may be vulnerable to a technically different pellet coating or matrix. A broader combination claim can create more meaningful settlement leverage but may face validity scrutiny where prior art discloses coadministration of memantine and donepezil.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not necessarily a new excipient molecule. It is a qualified excipient and process package that reduces development time and manufacturing variability.

High-value excipient opportunities

Controlled-release polymer systems

Suppliers can offer ethylcellulose, hypromellose, polyvinyl acetate, methacrylate copolymers, or polymer blends optimized for highly soluble amine drugs. The value proposition is predictable release across pH conditions, low coating weight, and reproducible scale-up.

Multiparticulate starter cores

Uniform sugar or microcrystalline-cellulose cores can improve drug-layering consistency. Narrow particle-size distribution is important because pellet size affects coating thickness, dissolution, capsule fill weight, and sprinkle mouthfeel.

Plasticizer systems

Triethyl citrate, polyethylene glycol, and related plasticizers can improve film flexibility. Suppliers that provide formulation guidance, coating-process windows, and stability data have a stronger position than commodity excipient vendors.

Taste-masking systems

Donepezil and memantine can produce bitter or unpleasant taste if pellets are chewed or retained in the mouth. Taste-masking coatings could support orally disintegrating, sprinkle, pediatric, geriatric, or dysphagia-oriented products, although any change in coating must preserve the intended release profile.

Low-moisture capsule technologies

Gelatin shell brittleness, capsule cross-linking, and moisture migration can affect stability. Low-moisture gelatin or hypromellose capsules may support improved storage performance, especially in humid markets.

Direct-compression and capsule-filling aids

Silicified microcrystalline cellulose, colloidal silicon dioxide, lubricants, and anti-static processing aids can reduce segregation and improve fill-weight control. These materials are particularly relevant where immediate-release donepezil powder is combined with larger controlled-release pellets.

How can companies differentiate new products?

The most defensible commercial opportunities are patient-use and manufacturing improvements rather than simple ingredient substitution.

Product concept	Commercial rationale	Main development barrier
Lower-cost generic capsule	Direct substitution for Namzaric	ANDA, bioequivalence, and patent risk
Sprinkle-optimized capsule	Supports dysphagia and caregiver administration	Dose recovery and food administration studies
Smaller capsule	Improves swallowing	Higher formulation concentration and fill-density requirements
Taste-masked pellets	Improves open-capsule acceptability	Coating may change release and exposure
Modified-strength product	Supports titration or special populations	May require a new regulatory strategy
Regional branded generic	Local pricing and distribution flexibility	Patent and regulatory differences by market
Co-packaged separate products	Lower development complexity	Loses single-capsule convenience
Combination product for institutional care	Simplifies medication administration	Reimbursement and formulary access

A co-packaged regimen of memantine extended release and donepezil may be easier to develop than a fixed-dose capsule but would compete on price rather than convenience. A fixed-dose generic has a stronger value proposition if it achieves reliable sprinkle performance and reduces caregiver administration burden.

What regulatory status and Orange Book issues apply?

Namzaric is an FDA-approved small-molecule combination product listed under NDA 206439.[1,4] Generic applicants would typically file ANDAs referencing the listed drug. The reference product’s combination nature does not automatically make the product a biologic or a 505(b)(2) product.

Regulatory review will focus on:

• Pharmaceutical equivalence.
• Bioequivalence for both active ingredients.
• Comparative dissolution.
• Stability.
• Capsule-opening and sprinkling performance.
• Labeling consistency.
• Manufacturing reproducibility.
• Patent certifications under the Hatch-Waxman framework.

The Orange Book should be reviewed for current listed patents, exclusivity codes, therapeutic-equivalence evaluations, and any changes to the reference product record.[4]

How does memantine-donepezil compare with separate-product therapy?

Attribute	Fixed-dose combination	Separate memantine and donepezil products
Pill burden	Lower	Higher
Dose flexibility	Lower	Higher
Manufacturing complexity	High	Moderate
Patient adherence	Potentially improved	Depends on regimen complexity
Generic substitution	Requires complex ANDA	Established products available
Caregiver administration	Simplified	More steps
Commercial differentiation	Stronger	Weaker
Formulation IP	Combination and release claims	Primarily individual product claims

The fixed-dose product is most attractive when the patient is stable on both drugs and requires a simple chronic regimen. Separate products remain preferable when clinicians need independent dose adjustments or when reimbursement does not support the combination.

Key Takeaways

• Namzaric combines memantine hydrochloride extended release and donepezil hydrochloride immediate release in four once-daily capsule strengths.
• The core excipient strategy is multiparticulate delivery with a controlled-release memantine pellet population and an immediate-release donepezil component.
• Ethylcellulose, hypromellose, plasticizers, starter cores, binders, and capsule-shell materials are central to product performance.
• The most important technical requirements are dissolution control, dose uniformity, sprinkle performance, stability, and scale-up reproducibility.
• Namzaric’s regulatory exclusivity was distinct from its formulation patent position. The product’s three-year new-application exclusivity period was relevant after its 2014 approval, while listed patents could create later entry barriers.
• Biosimilar risk is not applicable because the product contains small-molecule active ingredients.
• The strongest commercial opportunities are complex generics, sprinkle-optimized products, taste-masked multiparticulates, low-moisture capsules, and excipient-process packages.
• Patent strength is concentrated in the combination and release architecture, not in memantine or donepezil composition-of-matter protection.

FAQs

Can memantine hydrochloride and donepezil hydrochloride be compressed into one immediate-release tablet?

Yes, but an immediate-release tablet would not replicate Namzaric’s extended-release memantine profile without additional release-control technology. It would require a different regulatory and bioequivalence strategy.

Which excipient is most important for memantine extended release?

The release-controlling polymer system is most important. Ethylcellulose-based membranes, often combined with hydrophilic polymers and plasticizers, can regulate diffusion from multiparticulate pellets.

Is a sprinkle formulation commercially valuable for Alzheimer’s disease patients?

Yes. Many patients with moderate-to-severe Alzheimer’s disease have swallowing difficulties or depend on caregivers. A reliable sprinkle presentation can differentiate a product, provided that the pellets remain intact and dose delivery is reproducible.

Does a generic Namzaric product need to use the same excipients as the reference product?

No. A generic product generally does not need to use identical inactive ingredients, but its formulation must meet applicable equivalence, safety, stability, dissolution, and labeling requirements.

Can excipient suppliers obtain patent protection around a memantine-donepezil formulation?

Potentially. Patentable subject matter may include a novel polymer combination, coating architecture, pellet-size distribution, stability improvement, taste-masking system, or manufacturing process. Patentability depends on novelty, nonobviousness, enablement, and claim scope.

References

1. U.S. Food and Drug Administration. (2014). Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules: Prescribing information. FDA.

2. U.S. District Court for the District of Delaware. Forest Laboratories, LLC v. Zydus Pharmaceuticals (USA) Inc., patent litigation records concerning Namzaric.

3. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,846,100: Pharmaceutical compositions comprising memantine and donepezil. USPTO.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.